NHRI licenses DBPR216, an anti-cancer developmental drug candidate, to Taivex Therapeutics Corp

The National Health Research Institutes (NHRI) and Taivex Therapeutics Corp. (Taivex) are pleased to announce the technology transfer of DBPR216, a potential anti-cancer developmental drug candidate, effective April 8. NHRI’s licensing of DBPR216, a multi-targeted tyrosine kinase inhibitor, to Taivex will further the drug’s preclinical and clinical development and advance its commercialization.

Activating mutations of receptor tyrosine kinase c-KIT are fundamental to the pathogenesis of most gastrointestinal stromal tumors (GISTs). Two receptor tyrosine kinases, KIT and FLT3, are frequently mutated in acute myeloid leukemia (AML). DBPR216, discovered by Institute of Biotechnology and Pharmaceutical Research (IBPR) which is one of the institutes under NHRI, shows very good inhibitory effects on mutant c-KIT and FLT3 kinases, and it exhibits excellent growth inhibition against GIST and AML cell lines. Moreover, DBPR216 shows excellent anti-tumor response to the c-KIT mutant GIST and AML xenograft models and the FLT3-ITD mutant AML xenograft model. So far the data show the anti-tumor effects of DBPR216 on GIST tumor xenografts are superior to those of the present standard first-, second-, and third-line drugs (Glivec, Sutent, and Stivarga, respectively). DBPR216 can be expected to enter Phase I clinical trials within three years.

This technology transfer, through which Taivex will carry on the preclinical and clinical development of DBPR216, furthers NHRI’s mission of accelerating the industrialization of novel drug R&D; proves NHRI’s abundant energy in drug discovery and innovation; and demonstrates the success of the government’s promotion of the biotechnology and pharmaceutical industries in Taiwan through a collaborative model among the government (especially the Ministry of Science and Technology, the Ministry of Health and Welfare, and the Ministry of Economic Affairs), research institutes, and industry. We expect DBPR216 will be marketed and contribute to the treatment of GIST and AML patients around the world by 2029.

About NHRI
The National Health Research Institutes, established in January 1996, is a non-profit organization dedicated to the enhancement of medical research and the general well-being of the people in Taiwan. For more information, please visit http://english.nhri.org.tw/

About IBPR
As one of NHRI’s research institutes, the Institute of Biotechnology and Pharmaceutical Research (IBPR) aims to engage in cutting-edge biomedical research for the betterment of health and quality of life for humanity. IBPR emphasizes first-in-class/best-in-class drug discovery and seeks to become the center of excellence for innovative drug discovery in Asia. For more information, please visit https://ibpr.nhri.org.tw/en/

About Taivex
Taivex Therapeutics Corp., founded in 2010, focuses on the development of novel, niche, and targeted anti-cancer drugs. Taivex’s core proprietary technology platform, which is licensed from the University of Texas at San Antonio, identifies compounds that inhibit Hec1-Nek2 interaction. In 2016, Taivex licensed another anti-cancer drug, DBPR115, from NHRI; this drug is in the preclinical stage and will have its IND application filed this year.
Taivex Therapeutics Corp. is located in Taipei, Taiwan. For more information, please visit http://www.taivex.com/

Contact information
Nathalie Huang
Secretariat
National Health Research Institutes
tel.: +886-37-246-166 ext. 32113
E-mail: nathalie@nhri.org.tw

Share Button

Comments are closed.